IMG20260622101809.jpg

Interpret this table in simplified way

Table 15-4: Evaluating Acid-Base Status in Respiratory Acidosis

The table uses a Ratio = ΔH⁺ / ΔPco₂ (change in hydrogen ions divided by change in CO₂) to figure out what type of acid-base disorder is present.

Here's the simplified breakdown:

The Ratio and What It Means

Ratio	What's Happening	Diagnosis
< 0.3	H⁺ rise is much less than expected for the CO₂ rise	Chronic respiratory acidosis + Metabolic alkalosis (the body is over-compensating)
= 0.3	H⁺ rise matches what chronic CO₂ retention would cause	Pure Chronic Respiratory Acidosis
0.3 - 0.8	H⁺ rise is between chronic and acute expected values	Chronic respiratory acidosis + Acute respiratory acidosis (mixed) - check pH
= 0.8	H⁺ rise matches what acute CO₂ retention would cause	Pure Acute Respiratory Acidosis
> 0.8	H⁺ rise is more than even acute respiratory acidosis explains	Acute or Chronic Respiratory Acidosis + Metabolic Acidosis

The Core Concept in Simple Terms

When CO₂ rises (respiratory acidosis), H⁺ also rises - but by how much tells you the story:
- Chronic respiratory acidosis: kidneys compensate over days, so H⁺ rises only a little per unit CO₂ (ratio ~0.3)
- Acute respiratory acidosis: no kidney compensation yet, so H⁺ rises more per unit CO₂ (ratio ~0.8)
- If H⁺ rises even more than 0.8 → something extra is adding acid = metabolic acidosis on top
- If H⁺ rises less than 0.3 → something is neutralizing acid = metabolic alkalosis on top

Explain how to calculate ΔH⁺ and ΔPco₂ from lab values

How to Calculate ΔH⁺ and ΔPco₂ from ABG Values

Both values come from an Arterial Blood Gas (ABG) report.

Step 1: Get Your Lab Values

From the ABG, you need:

pH (to convert to H⁺)
PaCO₂ (directly given in mmHg)

Normal reference values:

Parameter	Normal Value
pH	7.40
H⁺	40 nmol/L
PaCO₂	40 mmHg

Step 2: Convert pH → H⁺ Concentration

pH is a logarithmic scale, so you can't subtract it directly. You must convert to H⁺ first.

The Easy Clinical Formula (the "80 minus" rule):

H⁺ (nmol/L) ≈ 80 − (last two digits of pH)

pH	Calculation	H⁺
7.40	80 - 40	= 40 nmol/L
7.30	80 - 30	= 50 nmol/L
7.20	80 - 20	= 60 nmol/L
7.50	80 - 50	= 30 nmol/L

This formula is accurate between pH 7.20 - 7.55. Outside this range, use the exact formula below.

Exact Formula (if needed):

H⁺ = 10^(9 − pH) nmol/L

Example: pH 7.30 → H⁺ = 10^(9−7.30) = 10^1.70 = 50 nmol/L

Step 3: Calculate ΔH⁺ and ΔPco₂

Once you have H⁺, both deltas are simple subtractions from normal:

ΔH⁺ = Patient's H⁺ − 40

ΔPco₂ = Patient's PaCO₂ − 40

Worked Example

ABG result: pH = 7.24, PaCO₂ = 60 mmHg

Step 1 - Convert pH to H⁺:

H⁺ = 80 − 24 = 56 nmol/L

Step 2 - Calculate deltas:

ΔH⁺ = 56 − 40 = 16
ΔPco₂ = 60 − 40 = 20

Step 3 - Calculate ratio:

Ratio = 16 ÷ 20 = 0.8

Interpretation: Ratio = 0.8 → Pure Acute Respiratory Acidosis ✓

Quick Summary

1. Read pH and PaCO₂ from ABG
2. H⁺ = 80 − (last 2 digits of pH)
3. ΔH⁺ = H⁺ − 40
4. ΔPco₂ = PaCO₂ − 40
5. Ratio = ΔH⁺ ÷ ΔPco₂ → look up in table

The whole calculation takes about 30 seconds once you memorize the 80-minus rule.

Different sodium bicarbonate preparation and its infusion dose

This is a medical question, so let me check the medical library first.

Searching sources...

Reading File

Finding Sources

Searching the Web

sodium bicarbonate preparations IV infusion dose concentrations clinical

Reading File

Here is a complete breakdown of all sodium bicarbonate preparations and their dosing:

Sodium Bicarbonate (NaHCO₃) - Preparations & Dosing

Part 1: Available Preparations

A. IV Injection (Bolus) Vials/Ampules

Concentration	Strength	Volume	Content	Tonicity
8.4%	1 mEq/mL	50 mL	50 mEq per ampule	Hypertonic (2000 mOsm/L)
7.5%	0.9 mEq/mL	50 mL	44.6 mEq per ampule	Hypertonic
4.2%	0.5 mEq/mL	100 mL	50 mEq per vial	Less hypertonic

8.4% is the most commonly used in emergencies - each 50 mL ampule = 1 mEq/mL, easy to dose.

B. IV Infusion (Drip) Bags

Preparation	Volume	NaHCO₃ content	Carrier fluid
1.26%	500 mL	75 mEq	Isotonic (near-physiologic)
50 mEq in 1L	1000 mL	50 mEq	D5W, 0.45% NS, or sterile water
75 mEq in 1L	1000 mL	75 mEq	D5W or 0.45% NS
100 mEq in 1L	1000 mL	100 mEq	D5W or 0.45% NS
150 mEq in 1L	1000 mL	150 mEq	D5W or sterile water

The 1.26% (isotonic) bag is safest for large-volume infusions - least risk of hypernatremia.

C. Oral Tablets

Form	Strength
NaHCO₃ tablets	325 mg or 650 mg (= 7.7 mEq per 650 mg tablet)
KHCO₃ tablets	25-50 mEq
KHCO₃-citric acid	20-40 mEq

Part 2: Dosing by Clinical Situation

1. Metabolic Acidosis (General)

Formula:

Dose (mEq) = 0.3 × Weight (kg) × Base Deficit

Give half the calculated dose first, then recheck ABG
Non-urgent: 2-5 mEq/kg IV over 4-8 hours
Never correct fully in one go - risk of overshoot alkalosis

2. Cardiac Arrest

Initial bolus: 1 mEq/kg IV push (= 1 mL/kg of 8.4%)
Repeat: 0.5 mEq/kg every 10 minutes
Guided by ABG

3. Wide QRS / Sodium Channel Blockade (e.g., TCA overdose, beta-blocker overdose)

Bolus: 2-3 mEq/kg rapid IV over 1-2 minutes
- 70 kg patient = 140-210 mEq = 3-4 ampules of 8.4%
Goal: Narrow QRS to < 100-120 ms
Maintenance infusion: 3 ampules NaHCO₃ + 1L D5W, run at twice maintenance rate
Target serum pH: 7.50-7.55

4. Hyperkalemia (Subacute)

Use isotonic (1.26%) infusion - NOT hypertonic push
Effect on K⁺ takes 4-6 hours (not useful acutely on its own)
Hypertonic bolus does NOT lower K⁺ acutely and risks hypernatremia

5. Urinary Alkalinization (e.g., salicylate toxicity, rhabdomyolysis)

Add 150 mEq NaHCO₃ to 850 mL D5W (= 1L bag)
Infuse to maintain urine pH > 7.5 and serum pH 7.50-7.55
Monitor urine pH hourly

Part 3: Key Practical Points

Point	Detail
Central line preferred for 8.4%	Hypertonic - can cause tissue necrosis if extravasated
Peripheral use	Dilute 8.4% → use 1.26% or dilute further
Monitor:	ABG, serum Na⁺, K⁺, ionized Ca²⁺, urine pH
Caution:	Lowers ionized Ca²⁺ - do not mix with calcium solutions
Ventilation	Increase rate during infusion - NaHCO₃ generates CO₂
Overshoot risk	Never fully correct acidosis in one session

Sources: StatPearls (NCBI), Tintinalli's Emergency Medicine, Brenner & Rector's The Kidney, FDA prescribing information

Difference between ABG and VBG

ABG comes from arterial blood (usually radial artery), while VBG comes from venous blood. pH and HCO₃ are very similar between the two, but PO₂ is only reliable from ABG. VBG is easier and safer to obtain.

Searching sources...

Reading File

Searching the Web

ABG vs VBG difference clinical correlation pH PCO2 PO2 accuracy

Finding Sources

Reading File

Here is a complete, simplified comparison:

ABG vs VBG - Complete Comparison

Part 1: Basic Differences

Feature	ABG	VBG
Blood source	Artery (usually radial)	Vein (peripheral or central)
Pain level	More painful	Less painful
Difficulty	Technically harder	Easier
Needle-stick risk	Higher (arterial pressure)	Lower
Complications	Arterial spasm, hematoma, nerve injury, thrombosis	Minimal
Allen's test needed?	Yes (before radial puncture)	No

Part 2: How the Values Compare

Parameter	ABG (Normal)	VBG (Normal)	Difference	Reliable on VBG?
pH	7.35-7.45	7.31-7.41	VBG ~0.03-0.05 lower	✅ Yes
PCO₂	35-45 mmHg	41-51 mmHg	VBG ~4-6 mmHg higher	✅ Yes (screening)
HCO₃	22-26 mEq/L	22-26 mEq/L	Essentially same	✅ Yes
Base Excess	-2 to +2	Similar	Minimal difference	✅ Yes
PO₂	80-100 mmHg	30-50 mmHg	Very different	❌ No - use SpO₂
Lactate	<2 mmol/L	Similar	Minimal difference	✅ Yes

The key rule: VBG tells you about acid-base status reliably. It tells you nothing about oxygenation - use pulse oximetry (SpO₂) for that instead.

Part 3: The Conversion Formula

If you have a VBG and need to estimate ABG values:

Estimated ABG pH  = VBG pH + 0.05
Estimated ABG PCO₂ = VBG PCO₂ − 5 mmHg

This adjustment improves diagnostic accuracy from ~45% to ~74% (BUMC study, n=187 ICU patients).

Part 4: When to Use Each

✅ VBG is sufficient for:

Metabolic acidosis monitoring (DKA, renal failure)
Screening for hypercarbia (if VBG PCO₂ normal → arterial PCO₂ almost certainly normal)
COPD exacerbation (acid-base assessment)
Electrolyte monitoring (Na⁺, K⁺, Cl⁻, iCa²⁺)
Lactate measurement
Serial monitoring (reduces repeated arterial stabs)

❌ ABG is required when:

Oxygenation status is the primary concern (PaO₂ needed)
Respiratory failure assessment (exact PaCO₂ matters)
VBG PCO₂ is elevated (> 45 mmHg) - need the exact arterial value
Major trauma
Titrating mechanical ventilation
VBG shows abnormal result and exact arterial values are needed to guide management

Part 5: Quick Memory Aid

VBG = ACID-BASE ✅ + OXYGENATION ❌
ABG = ACID-BASE ✅ + OXYGENATION ✅

If VBG is normal → ABG is almost certainly normal
If VBG is abnormal → may need ABG to confirm and quantify

Sources: Harriet Lane Handbook (23rd ed.), Rosen's Emergency Medicine, emDocs clinical review, BUMC prospective study (n=187), Springer International Journal of Emergency Medicine

Give me full note on atrial fibrillation pathophysiology, etiology, diagnosis and management according to latest guideline for emergency physician.

Finding Sources

Searching PubMed

"atrial fibrillation"[MeSH Terms] AND "guideline"[pt]

Searching the Web

atrial fibrillation 2023 2024 ACC AHA ESC guidelines emergency management

Reading File

Finding Sources

Reading Web Page

https://amu.hr/article/current-management-of-atrial-fibrilla…

Reading File

Finding Sources

Reading File

Here is the full clinical note on Atrial Fibrillation for the emergency physician:

Atrial Fibrillation - Emergency Physician's Complete Note

Guidelines referenced: 2023 ACC/AHA/ACCP/HRS (Circulation 2024;149:e1-e156) | 2024 ESC/EACTS Guidelines (Eur Heart J 2024;45:3314)

1. DEFINITION & CLASSIFICATION

AF is the most common sustained cardiac arrhythmia, characterized by disorganized atrial electrical activity replacing normal sinus rhythm.

2023 ACC/AHA Staging (new concept - replaces old terminology)

Stage	Description
Stage 1	At risk for AF (risk factors present, no AF yet)
Stage 2	Pre-AF (structural/electrical changes, no documented AF)
Stage 3	AF present - subdivided as:
3a	Paroxysmal - terminates spontaneously, usually <7 days
3b	Persistent - sustained >7 days, requires cardioversion
3c	Long-standing persistent - continuous AF >12 months
3d	Successful AF ablation
Stage 4	Permanent AF - rhythm control no longer pursued

2. PATHOPHYSIOLOGY

Triggering Mechanism

Multiple micro-reentry circuits within atrial tissue generate 300-600 atrial impulses/min
The AV node acts as a gatekeeper, allowing only some impulses to reach the ventricles (typically 100-180 bpm at rest)
Result: irregularly irregular ventricular response

Electrophysiologic Substrate

Pulmonary vein foci - ectopic firing from pulmonary vein ostia is the most important trigger (basis of ablation therapy)
Atrial fibrosis and remodeling - structural changes that perpetuate re-entry
Electrical remodeling - AF begets AF; the longer AF persists, the harder it is to convert ("AF promotes AF")

Hemodynamic Consequences

Loss of atrial kick - normally contributes 15-30% of cardiac output; loss is particularly harmful in patients with diastolic dysfunction or hypertrophic cardiomyopathy
Rapid ventricular rate - reduces diastolic filling time, drops stroke volume
Tachycardia-induced cardiomyopathy - prolonged rapid AF can cause reversible LV dysfunction
Thrombus formation - stasis in left atrial appendage (LAA) → thrombus → systemic embolization → stroke (3-5x increased stroke risk)

3. ETIOLOGY

Cardiac Causes

Cause	Notes
Hypertensive heart disease	Most common overall cause
Ischemic heart disease / MI	Especially after acute MI
Valvular disease	Mitral disease most strongly associated
Congestive heart failure	Up to 1/3 of CHF patients have AF
Cardiomyopathy	Dilated and hypertrophic
Pericarditis / myocarditis	Inflammatory trigger
Cardiac surgery	Post-op AF very common
WPW / Accessory pathway	Special management consideration
Sick sinus syndrome	Brady-tachy syndrome

Non-Cardiac / Systemic Causes

Cause	Notes
Hyperthyroidism	Screen all new AF - get TSH
Pulmonary embolism	Acute right heart strain
Sepsis / infection	Systemic inflammation
Alcohol	"Holiday heart syndrome" - binge drinking
Catecholamine excess	Stress, pheochromocytoma, stimulants
Electrolyte disturbance	Hypokalemia, hypomagnesemia
Myocardial contusion	Trauma
Obstructive sleep apnea	Major modifiable risk factor
Obesity	Independent risk factor
Lone AF (idiopathic)	No identifiable cause, usually younger patients

4. CLINICAL PRESENTATION

Symptoms (variable)

Palpitations (most common)
Dyspnea / exercise intolerance
Chest discomfort
Fatigue / light-headedness
Syncope or pre-syncope
Silent AF - found incidentally on ECG; especially in elderly

Signs

Irregularly irregular pulse (hallmark)
Variable pulse deficit (radial vs apical)
Signs of hemodynamic compromise (hypotension, diaphoresis, pulmonary edema) in unstable AF

Red Flags in ED

HR > 150 with hypotension → unstable → immediate cardioversion
Wide QRS with AF → consider WPW or aberrancy (never give AV nodal blockers in WPW)
New onset AF with chest pain → ACS trigger or consequence
Stroke symptoms + AF → urgent imaging

5. DIAGNOSIS

ECG Findings (Gold Standard)

Absent P waves (replaced by fibrillatory "f" waves - coarse or fine)
f waves best seen in lead V1 and inferior leads
Irregularly irregular RR intervals - the hallmark
QRS usually narrow (unless aberrancy/BBB/WPW)

ECG Pitfalls

Scenario	Finding	Action
Wide QRS + irregular rhythm + HR >200	Suspect WPW	Avoid AV nodal blockers → use procainamide
Wide QRS + irregular + HR <200	BBB with AF	AV nodal blocking safe
Ashman phenomenon	Long-short cycle → aberrant RBBB beat	Don't mistake for PVC/VT
Regular rhythm in "AF"	May be flutter with fixed block	Check for flutter waves

Workup in ED

Test	Purpose
12-lead ECG	Confirm AF, look for WPW, ischemia, LVH
Troponin	Exclude ACS as trigger or consequence
BMP / electrolytes	K⁺, Mg²⁺, renal function (for drug dosing)
TSH	Rule out thyrotoxicosis
CBC	Anemia, infection
Chest X-ray	Heart failure, pulmonary pathology
Coagulation (INR/PT)	If anticoagulation planned or patient on warfarin
Echo (bedside or formal)	LV function, valve disease, clot if available

6. EMERGENCY MANAGEMENT

Step 1: Is the Patient Hemodynamically UNSTABLE?

Unstable = hypotension, acute pulmonary edema, altered consciousness, ongoing ischemia

→ Immediate synchronized DC cardioversion (do NOT delay for anticoagulation)
Give anticoagulation as soon as possible before/during cardioversion (LMWH or UFH bolus)
Start at 120-200 J biphasic (biphasic preferred - 94% vs 84% efficacy vs monophasic)
Continue OAC for at least 4 weeks post-cardioversion

Step 2: Stable Patient - Rate vs. Rhythm Control Decision

Rate Control Strategy

First-line for: older patients, asymptomatic/mildly symptomatic, heart failure with low EF (avoid non-DHP CCBs), AF >48 hours without anticoagulation

Drug	Dose	Notes
Metoprolol IV	2.5-5 mg IV over 2 min, repeat q5min up to 15 mg	Beta-blocker of choice; safe in HF
Diltiazem IV	0.25 mg/kg over 2 min, then 5-15 mg/hr infusion	Highly effective; avoid in HF with low EF
Verapamil IV	2.5-5 mg over 2 min, repeat 5-10 mg	Avoid in HF
Digoxin IV	0.5 mg IV loading, then 0.25 mg q6h	Slow onset; good for HF + AF
Amiodarone IV	150 mg over 10-15 min	Use when others contraindicated; also has rhythm control effect

Target heart rate:

Resting HR < 110 bpm acceptable if asymptomatic with preserved LV function (lenient strategy)
Resting HR < 80 bpm if symptomatic or heart failure (strict strategy - AHA Class IIa)

Rhythm Control Strategy

Prefer for: new-onset AF <24-48 hours, younger/symptomatic patients, hemodynamically unstable, heart failure with reduced EF (catheter ablation - NOT antiarrhythmic drugs)

A. Pharmacologic Cardioversion (chemical cardioversion)

Drug	Dose	Notes
Procainamide	30-50 mg/min IV up to 18-20 mg/kg (max 12 mg/kg in CHF)	First-line if WPW suspected
Ibutilide	0.015-0.02 mg/kg IV over 10-15 min	Highest conversion rate; avoid in structural heart disease
Amiodarone	150 mg IV over 10-15 min → 1 mg/min x6h → 0.5 mg/min x18h	Safe in structural heart disease
Flecainide	300 mg oral ("pill-in-pocket")	Contraindicated in structural/ischemic heart disease
Propafenone	600 mg oral	Same contraindications as flecainide

B. Electrical Cardioversion (DC cardioversion)

Synchronized cardioversion - mandatory (avoids R-on-T)
Start: 120-200 J biphasic
Success rate higher than pharmacologic conversion
Combined strategy: pharmacologic first, then electrical if not converted in 30 min → reduces need for electrical shock in ~50% of cases
Up to 50% of new-onset AF converts spontaneously within 24 hours - observation is an option

Step 3: Anticoagulation Decision

AF Duration < 48 hours

Cardioversion can proceed without prior anticoagulation
Give anticoagulation before cardioversion regardless (LMWH or UFH bolus)
Continue OAC for at least 4 weeks post-cardioversion (post-cardioversion stunning risk)
Exception: patients without thromboembolic risk factors (CHA₂DS₂-VA = 0) who restore sinus rhythm within 24 hours may omit 4-week anticoagulation

AF Duration > 48 hours (or unknown duration)

Do NOT cardiovert unless:
- Patient has been on therapeutic anticoagulation for ≥3 weeks (DOAC adherence or INR ≥2.0), OR
- TEE performed showing no LAA thrombus
Then cardiovert and continue OAC ≥4 weeks post-cardioversion

Long-term Anticoagulation: CHA₂DS₂-VASc Score

Risk Factor	Points
C - Congestive heart failure	1
H - Hypertension	1
A₂ - Age ≥ 75 years	2
D - Diabetes mellitus	1
S₂ - Prior Stroke/TIA/embolism	2
V - Vascular disease (MI, PAD, aortic plaque)	1
A - Age 65-74 years	1
Sc - Sex category (female)	1
Maximum	9

Score	Recommendation
0 (male) / 1 (female)	No anticoagulation needed
1 (male)	Anticoagulation should be considered
≥2 (male) / ≥3 (female)	Oral anticoagulation recommended

DOAC Preferred Over Warfarin (2023 ACC/AHA, 2024 ESC - Class I)

DOAC	Dose (standard)	Notes
Apixaban	5 mg BD (2.5 mg BD if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5 mg/dL)	Lowest bleeding risk; preferred in most
Rivaroxaban	20 mg OD with evening meal	Once daily convenience
Dabigatran	150 mg BD (110 mg BD if age >75 or high bleed risk)	Only direct thrombin inhibitor
Edoxaban	60 mg OD (30 mg if CrCl 15-50, weight ≤60 kg)	Less data in ED
Warfarin	Target INR 2.0-3.0	Use only for valvular AF (mechanical valve, rheumatic mitral stenosis)

ESC 2024 recommends initiating DOAC in the ED for eligible high-stroke-risk AF patients - don't wait for outpatient follow-up.

Step 4: Special Situations

WPW + AF (Pre-excitation AF)

ECG: wide, irregular QRS, rate often >200 bpm
NEVER give: adenosine, diltiazem, verapamil, digoxin, amiodarone (all can accelerate accessory pathway conduction → VF)
Give: Procainamide IV (drug of choice) or immediate DC cardioversion if unstable

AF + Acute Heart Failure

Rate control with beta-blocker (metoprolol) or digoxin (avoid verapamil/diltiazem)
Early rhythm control via catheter ablation (not antiarrhythmic drugs) improves outcomes in HFrEF

AF + ACS

Urgent coronary angiography if ongoing ischemia
Triple therapy risk (OAC + dual antiplatelet) - minimize duration; usually move to dual therapy (OAC + P2Y12) after 1 week

Thyrotoxic AF

Beta-blockade for rate control (propranolol preferred - also blocks T4→T3 conversion)
Treat underlying thyroid disease
Cardioversion often deferred until euthyroid

Post-cardioversion Monitoring

Observe for minimum 30-60 minutes after cardioversion
Watch for: re-initiation of AF, bradycardia, thromboembolic events
80% of patients can be safely discharged from ED after successful rate/rhythm control

7. ED DISPOSITION GUIDE

Situation	Disposition
Successful rate/rhythm control, hemodynamically stable	Discharge with OAC + rate control + cardiology follow-up
Persistent AF, controlled rate, low-risk patient	Discharge with outpatient plan
Uncontrolled rate despite therapy	Admit
New heart failure, pulmonary edema, ongoing ischemia	Admit
Failed cardioversion, unstable	Admit (CCU/monitored bed)
Unknown AF duration, no anticoagulation, needs cardioversion	Admit or arrange TEE
Stroke/TIA associated with AF	Admit neurology/stroke team

8. AF-CARE Framework (2024 ESC - New Model)

The ESC 2024 guidelines restructure AF management around the AF-CARE model:

Letter	Principle
C	Comorbidity and risk factor management (weight, BP, diabetes, sleep apnea, alcohol)
A	Avoiding stroke and thromboembolism (anticoagulation)
R	Reducing symptoms (rate/rhythm control)
E	Evaluation and dynamic reassessment (regular follow-up, monitoring)

Quick Reference: ED Decision Tree

AF on ECG
    │
    ├─ UNSTABLE? (↓BP, pulmonary edema, altered consciousness)
    │       └─ YES → Immediate Synchronized DC Cardioversion + Anticoagulate ASAP
    │
    └─ STABLE?
            │
            ├─ Duration < 48h? → Cardiovert (electrical or pharmacologic)
            │       └─ Anticoagulate before + continue ≥4 weeks after
            │
            ├─ Duration > 48h? → Rate Control first
            │       └─ Cardiovert only after 3 weeks anticoagulation OR TEE clear
            │
            ├─ WPW suspected? → Procainamide or DC cardioversion ONLY
            │
            └─ All stable patients → Calculate CHA₂DS₂-VASc → Start DOAC if score ≥2

Sources: Rosen's Emergency Medicine (10th ed.) | Tintinalli's Emergency Medicine | Braunwald's Heart Disease | 2023 ACC/AHA/ACCP/HRS Guideline (PMID 38043043) | 2024 ESC Guidelines (PMID 39210723)This is a full emergency physician-oriented AF note covering everything from pathophysiology to the latest 2023 ACC/AHA and 2024 ESC guidelines. A few highlights to remember at the bedside:

WPW + AF is a trap - the wide irregular rhythm above 200 bpm needs procainamide or DC cardioversion, not AV nodal blockers
The 48-hour rule governs cardioversion safety without prior anticoagulation
ESC 2024 now recommends starting DOACs in the ED - don't defer to outpatient
80%+ of AF patients can be safely discharged from the ED after adequate rate/rhythm control
The new AF-CARE framework shifts focus toward managing underlying comorbidities (weight, OSA, hypertension, alcohol) as equal pillars alongside anticoagulation and rate/rhythm control

Pulmonary TB latest WHO update

Reading File

Searching the Web

WHO tuberculosis guidelines 2024 2025 latest update treatment

Searching PubMed

"tuberculosis"[MeSH Terms] AND "WHO" AND "guideline"[pt]

Finding Sources

Reading Web Page

https://www.who.int/news/item/08-10-2025-who-releases-new-gu…

Searching the Web

WHO consolidated guidelines tuberculosis module 4 2025 DS-TB DR-TB treatment update summary

Reading File

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC12248249

Reading File

Searching the Web

WHO 2025 Module 4 tuberculosis 4-month regimen isoniazid rifapentine moxifloxacin pyrazinamide DS-TB update

Finding Sources

Reading File

Now I have comprehensive information from textbooks, WHO guidelines, and the latest 2025 updates. Let me compile the full note.

Pulmonary Tuberculosis - Full Clinical Note with Latest WHO 2025 Updates

Guidelines referenced:

WHO Consolidated Guidelines Module 4 (April 2025) - DS-TB & DR-TB
WHO Module 6 (October 2025) - TB & Comorbidities (Undernutrition)
ATS/CDC/ERS/IDSA 2025 Clinical Practice Guideline (AJRCCM, January 2025)
WHO Global TB Report 2024

1. EPIDEMIOLOGY & BURDEN

TB remains the leading infectious disease killer globally (second only to COVID-19 in recent years)
10.8 million new TB cases reported in 2023 (WHO Global TB Report 2024)
~10% of all TB cases are drug-resistant (MDR/RR-TB)
High-burden countries: India, Indonesia, China, Philippines, Pakistan, Nigeria, Bangladesh, South Africa
Undernutrition is the single largest modifiable risk factor (new WHO 2025 focus)

2. ETIOLOGY & MICROBIOLOGY

Causative agent: Mycobacterium tuberculosis (aerobic, slow-growing, acid-fast bacillus)
Transmission: airborne - droplet nuclei (1-5 µm) from infectious pulmonary/laryngeal TB
Infectiousness depends on: cavitary disease, AFB smear positivity, cough frequency, inadequate ventilation
Only ~10% of infected immunocompetent individuals develop active disease over a lifetime (90% maintain latent infection)

Risk Factors for Progression from Latent to Active TB

Category	Examples
Immunosuppression	HIV (highest risk - 5-10% per year), TNF-α inhibitors, organ transplant, steroids
Malnutrition	BMI < 18.5 - major independent risk factor (new WHO emphasis 2025)
Diabetes mellitus	3x increased risk
Silicosis	Occupational exposure
CKD / dialysis	Uremia-induced immune suppression
Alcohol use disorder	Social + immune factors
Recent TB infection	<2 years from exposure
Extremes of age	Infants, elderly
Tobacco smoking	Independent risk factor

3. PATHOPHYSIOLOGY

Primary Infection

Bacilli inhaled → deposited in alveoli → engulfed by alveolar macrophages
Initially uncontrolled replication → spread to hilar lymph nodes (forming Ghon complex)
Immune response (2-8 weeks): T-cell mediated → granuloma formation
Granuloma = organized collection of activated macrophages, epithelioid cells, Langhans giant cells, lymphocytes
Central caseous necrosis occurs in granuloma - this is the hallmark of TB
In most: granuloma contains infection → latent TB infection (LTBI)

Reactivation (Post-Primary TB)

Latent bacilli survive inside granulomas for years/decades
Disruption of immune control → bacilli reactivate → progressive disease
Characteristic location: apical and posterior segments of upper lobes (high O₂ tension)
Cavity formation: caseous material liquefies → drains into bronchus → cavity + airborne transmission

Key Immunology Concepts

TST (Mantoux) and IGRA measure T-cell sensitization to TB antigens - positive = prior exposure
Cavity = most infectious (highest bacillary load + direct bronchial communication)
HIV coinfection: CD4 <200 → atypical presentation, no cavity, lower lobe involvement, smear-negative but culture-positive

4. CLINICAL PRESENTATION

Pulmonary TB (most common form)

Constitutional symptoms (all are subacute/chronic):

Persistent cough >2-3 weeks (productive or dry)
Fever (low-grade, afternoon)
Night sweats
Weight loss / anorexia
Fatigue
Hemoptysis (advanced/cavitary disease)
Note: up to 25% of culture-confirmed TB do not report cough

Physical Examination:

Often non-specific
Post-tussive rales in upper zones
Amphoric (hollow) breath sounds = cavity
Advanced: signs of consolidation, pleural effusion

Special Presentations

Scenario	Features
HIV coinfection (CD4 <200)	Lower lobe, no cavity, smear-negative, miliary pattern, normal CXR possible
Miliary TB	Hematogenous dissemination, 1-2 mm granulomas in lungs/liver/bone marrow, fundoscopic choroidal tubercles
Primary progressive	Middle/lower lobe consolidation, hilar adenopathy
Elderly	Atypical symptoms, lower lobe involvement, confused with other diagnoses
TB pleuritis	Exudative effusion, pleuritic chest pain, 3-6 months post-infection
IRIS (TB-immune reconstitution)	Paradoxical worsening after starting ART in HIV patients

5. DIAGNOSIS

Step 1: Suspect TB - Who to Test

Evaluate any patient with:

Cough >2 weeks + fever/sweats/weight loss
Hemoptysis
Abnormal CXR (upper lobe infiltrate, cavity, fibrosis)
Known HIV + any respiratory symptoms
Contact with confirmed TB case
Migrant from high-burden country

Step 2: Chest Radiography

Finding	Significance
Apical/posterior upper lobe infiltrate	Classic reactivation TB
Cavitation	Active, highly infectious
Tree-in-bud opacities	Endobronchial spread
Miliary pattern (1-2 mm nodules)	Hematogenous dissemination
Ghon complex / Ranke complex	Healed primary infection
Hilar adenopathy	Primary disease
Lower lobe + no cavity	HIV-related or primary
Normal CXR	Does NOT exclude TB in HIV patients

CT chest is more sensitive than plain CXR, especially in HIV or subtle disease.

Step 3: Microbiological Diagnosis

Test	Specimen	Sensitivity	Notes
Sputum AFB smear (ZN stain)	3 sputum samples (early morning)	45-80%	Rapid, cheap; positive = infectious; negative doesn't exclude
Sputum culture (gold standard)	Sputum/BAL	80-90%	Takes 2-8 weeks (liquid media 2-3 wks; solid 6-8 wks); confirms diagnosis & DST
Xpert MTB/RIF (GeneXpert)	Sputum/BAL/tissue	88% (smear+ve), 68% (smear-ve)	WHO first-line rapid test - 2 hours; also detects rifampicin resistance
Xpert MTB/RIF Ultra	Any	Slightly more sensitive than standard	Better for paucibacillary/extrapulmonary
TB-LAMP	Sputum	Similar to smear	Point-of-care; less widely available
Line probe assay (LPA)	Culture/sputum	-	Detects INH & RIF resistance (Hain GenoType)
Whole genome sequencing	Culture	Reference	Comprehensive DST; not yet routine

Step 4: Immunological Tests

Test	Method	Interpretation
Tuberculin Skin Test (TST/Mantoux)	5 TU PPD ID → read induration at 48-72h	≥5 mm (HIV/immunocompromised); ≥10 mm (high-risk); ≥15 mm (low-risk)
IGRA (QuantiFERON-TB Gold Plus / T-SPOT.TB)	Blood test; measures IFN-γ to ESAT-6/CFP-10	Preferred over TST in BCG-vaccinated individuals

TST/IGRA = positive means prior exposure / LTBI - DOES NOT diagnose active TB. Active TB requires microbiological confirmation.

Diagnostic Algorithm (WHO-recommended)

Symptoms of TB (cough >2wks, fever, weight loss, night sweats)
        ↓
Chest X-ray
        ↓
Xpert MTB/RIF (first-line WHO diagnostic tool)
    ├─ MTB detected, RIF resistant → MDR-TB workup → LPA/DST
    ├─ MTB detected, RIF sensitive → DS-TB treatment
    └─ MTB not detected → sputum culture + clinical evaluation
                          ├─ Culture positive → TB treatment
                          └─ Culture negative + clinical improvement on treatment → culture-negative TB

6. TREATMENT - LATEST WHO & ATS/CDC 2025 UPDATES

A. Drug-Susceptible TB (DS-TB)

Standard 6-Month Regimen (remains an alternative option - WHO 2022/2025)

2HRZE / 4HR

Phase	Duration	Drugs	Abbreviation
Intensive	2 months	Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E)	2HRZE
Continuation	4 months	Isoniazid (H) + Rifampicin (R)	4HR

🆕 NEW 4-Month Regimen (WHO 2022 / ATS/CDC/ERS/IDSA 2025 - Conditionally Recommended)

2HPZM / 2HPM (rifapentine-moxifloxacin regimen)

Phase	Duration	Drugs
Intensive	2 months	Isoniazid (H) + Rifapentine (P) + Pyrazinamide (Z) + Moxifloxacin (M)
Continuation	2 months	Isoniazid (H) + Rifapentine (P) + Moxifloxacin (M)

Key evidence: The TBTC Study 31 / ACTG A5349 trial showed this 4-month regimen is non-inferior to the 6-month standard (disease-free survival at 12 months, similar adverse events 18.8% vs 19.3%)

Eligibility (≥12 years old):

Drug-susceptible pulmonary TB confirmed
NOT for: confirmed/suspected MDR-TB, HIV on efavirenz-based ART (drug interaction with rifapentine), pregnancy (insufficient data), extrapulmonary TB (evidence limited)

Dosing (by weight - all taken daily with food):

Drug	40-55 kg	56-75 kg	76-90 kg
Isoniazid	300 mg	300 mg	300 mg
Rifapentine	900 mg	1200 mg	1500 mg
Moxifloxacin	400 mg	400 mg	400 mg
Pyrazinamide (intensive phase only)	1000 mg	1500 mg	2000 mg

Always give pyridoxine (B6) 25-50 mg/day with isoniazid to prevent peripheral neuropathy.

🆕 4-Month Regimen for Children (Non-Severe TB, 3 months - 16 years)

2HRZE / 2HR (instead of the standard 2HRZE/4HR)

WHO now recommends the shorter 4-month regimen for children with non-severe TB (no suspicion of MDR/RR-TB)
Non-severe = peripheral lymphadenopathy, uncomplicated pulmonary disease without cavitation

B. Drug-Resistant TB (DR-TB)

Definitions

Term	Definition
MDR-TB	Resistant to isoniazid AND rifampicin
RR-TB	Rifampicin-resistant (treated same as MDR-TB)
Pre-XDR-TB	MDR/RR-TB + resistant to any fluoroquinolone
XDR-TB	MDR/RR-TB + resistant to fluoroquinolone + bedaquiline OR linezolid

🆕 BPaLM Regimen - NOW Preferred for MDR/RR-TB (WHO 2022 onwards, reinforced 2025)

6 months - BPaLM

Drug	Dose
B - Bedaquiline	400 mg OD x 2 weeks → 200 mg 3x/week x 22 weeks
Pa - Pretomanid	200 mg OD
L - Linezolid	600 mg OD (may reduce to 300 mg for toxicity)
M - Moxifloxacin	400 mg OD

If fluoroquinolone-resistant: use BPaL (without moxifloxacin) - same duration

Evidence: ZeNix and TB-PRACTECAL trials demonstrated BPaLM superior to the older 9-20 month injectable-based regimens with fewer adverse events and better treatment success rates.

WHO strongly recommends: Injectable agents (amikacin, kanamycin, capreomycin) are no longer preferred in MDR-TB - they are relegated to salvage regimens only.

Grouping of DR-TB Drugs (WHO Priority)

Group	Drugs	Role
Group A (always include if possible)	Levofloxacin OR Moxifloxacin, Bedaquiline, Linezolid	Core agents
Group B (add to complete regimen)	Clofazimine, Cycloserine/Terizidone	Add-ons
Group C (when Groups A&B insufficient)	Ethambutol, Delamanid, Pyrazinamide, Imipenem-cilastatin, Amikacin, Ethionamide, PAS	Last resort

C. Latent TB Infection (LTBI) - Preventive Therapy

Regimen	Duration	Notes
1HP (Isoniazid + Rifapentine weekly)	1 month (12 doses)	Preferred - shortest, highest completion
3HP (Isoniazid + Rifapentine weekly)	3 months (12 doses)	WHO preferred option
3HR (Isoniazid + Rifampicin daily)	3 months	Alternative
6H (Isoniazid daily)	6 months	Alternative; 9H also acceptable

7. WHO 2025 NEW UPDATES - SUMMARY

Module 4 Update (April 15, 2025)

4-month DS-TB regimen (2HPZM/2HPM) now formally included alongside the 6-month standard
Updated evidence for BPaLM as preferred MDR-TB regimen with refined dosing guidance
New guidance on treatment monitoring - culture conversion at 2 months remains key milestone
Strengthened recommendations for DST before treatment for all patients

Module 6 Update (October 7, 2025) - TB & Undernutrition

Nutritional assessment and counselling mandatory for ALL people with TB and household contacts
Nutritional interventions recommended for all TB patients with undernutrition (regardless of age, drug resistance, pregnancy, or severity)
Food assistance to household contacts in food-insecure settings to prevent TB (supported by RATIONS trial evidence)
Operational handbook released to support country-level implementation

8. MONITORING & FOLLOW-UP

Timepoint	Action
Baseline	Sputum AFB x3, culture, LFTs, CBC, creatinine, uric acid, visual acuity (if ethambutol)
2 months (end of intensive phase)	Repeat sputum culture - culture conversion is KEY prognostic marker
Monthly	Clinical assessment, symptom review, adherence check
End of treatment	Sputum smear + culture; CXR
Adverse effects monitoring	LFTs monthly (isoniazid/rifampicin hepatotoxicity); vision (ethambutol); hearing (aminoglycosides); QTc (bedaquiline, fluoroquinolones, clofazimine)

Drug-induced Hepatotoxicity (DILI) - Threshold for stopping

Stop hepatotoxic anti-TB drugs if: ALT >3x ULN with symptoms OR ALT >5x ULN without symptoms

9. INFECTION CONTROL

Airborne precautions: N95 respirator for healthcare workers (not surgical mask)
Negative pressure isolation rooms for hospitalized patients
Patient education: cover cough, natural ventilation
Continue isolation until: 3 consecutive negative sputum smears (after starting treatment)
TB is notifiable in virtually all countries

10. TB SPECIAL POPULATIONS

Population	Key Considerations
HIV + TB	Start TB treatment FIRST → add ART within 2-8 weeks (2 weeks if CD4 <50); use rifabutin instead of rifampicin with PIs; beware IRIS
Pregnancy	2HRZE/4HR standard regimen (rifampicin + pyrazinamide generally safe); avoid aminoglycosides (ototoxicity); pyridoxine essential
Children	4-month regimen for non-severe TB now recommended; weight-based dosing
Diabetes	Monitor glycaemia closely; rifampicin reduces OHG levels
CKD/Dialysis	Avoid ethambutol (accumulates); adjust pyrazinamide; rifampicin dose unchanged
Liver disease	Avoid pyrazinamide if severe; monitor LFTs closely

11. END TB STRATEGY TARGETS (2030)

90% reduction in TB deaths (vs 2015)
80% reduction in TB incidence rate
No TB-affected families facing catastrophic costs
Key 2027 milestone: license at least one new TB vaccine

Stroke recent update 2026

Finding Sources

Searching PubMed

"ischemic stroke"[MeSH Terms] AND "guideline"[pt]

Searching the Web

stroke guidelines 2025 2026 AHA ASA update ischemic stroke treatment thrombolysis thrombectomy

Excellent - there's a brand new AHA/ASA 2026 guideline published January 26, 2026. Let me get full details on it plus core textbook content.

Reading Web Page

https://www.tctmd.com/news/ahaasa-release-new-comprehensive-…

Reading Article

PMID: 41582814

Finding Sources

Reading File

Searching the Web

2026 AHA ASA stroke guideline blood pressure management thrombectomy window extended pediatric dysphagia secondary prevention

Reading File

Reading Web Page

https://recapem.com/update-on-management-of-acute-ischemic-s…

Stroke - Full Clinical Note with 2026 Updates

Primary Guideline: AHA/ASA 2026 Guideline for the Early Management of Patients with Acute Ischemic Stroke Published: January 26, 2026 | Stroke journal | DOI: 10.1161/STR.0000000000000513 (Replaces 2018 guidelines and 2019 update)

Also referenced: ESO 2025 BP update (Eur Stroke J, May 2026) | ESO 2024 PFO guidelines | ILEP 2026 lipid management consensus

1. STROKE OVERVIEW & CLASSIFICATION

Definition

Stroke = sudden-onset focal neurological deficit due to vascular brain injury, lasting >24 hours (or any duration with imaging confirmation)

Types

Type	Proportion	Mechanism
Ischemic stroke	~87%	Thrombotic / embolic / small vessel occlusion
Intracerebral hemorrhage (ICH)	~10%	Hypertensive rupture / amyloid angiopathy
Subarachnoid hemorrhage (SAH)	~3%	Aneurysmal rupture

TOAST Classification (Ischemic Stroke Subtypes)

Subtype	Features
Large artery atherosclerosis	Stenosis/occlusion >50% of major artery; cortical or cerebellar deficit
Cardioembolic	Cardiac source (AF, valvular, LV thrombus); sudden onset, maximal at onset
Small vessel (lacunar)	Deep penetrating artery; classic lacunar syndromes; no cortical features
Other determined etiology	Coagulopathy, dissection, vasculitis, CADASIL
Cryptogenic	No cause found despite workup

2. PATHOPHYSIOLOGY

Ischemic Penumbra Concept

Core: irreversibly infarcted tissue (CBF < 10 mL/100g/min) - cannot be saved
Penumbra: ischemic but viable tissue (CBF 10-20 mL/100g/min) - TARGET of reperfusion therapy
Time is brain: ~1.9 million neurons lost per minute in untreated stroke
The penumbra-to-core ratio (mismatch) drives eligibility for extended-window treatment

Mechanisms of Ischemic Injury

ATP depletion → failure of Na⁺/K⁺ ATPase → cellular swelling
Glutamate excitotoxicity → calcium influx → mitochondrial dysfunction
Free radical production → lipid peroxidation
Inflammation → cytokine release → secondary injury
Blood-brain barrier breakdown → vasogenic edema

Hemorrhagic Transformation

Can occur spontaneously or after reperfusion therapy
Large infarct core, high BP, delayed reperfusion = risk factors
Types: HI1, HI2 (petechial), PH1, PH2 (parenchymal hematoma - PH2 = clinical worsening)

3. RISK FACTORS

Modifiable	Non-modifiable
Hypertension (most important)	Age (risk doubles per decade >55)
Atrial fibrillation	Male sex (slightly)
Diabetes mellitus	Race (Black > White)
Dyslipidemia	Family history
Smoking	Prior stroke/TIA
Obesity / physical inactivity	Hereditary conditions (CADASIL, etc.)
Excessive alcohol
OSA
Patent foramen ovale (PFO)

4. CLINICAL PRESENTATION

FAST / BE-FAST Recognition

Letter	Symptom
B	Balance - sudden loss
E	Eyes - sudden vision loss or double vision
F	Face drooping (unilateral)
A	Arm weakness
S	Speech difficulty (slurred or incomprehensible)
T	Time - call emergency services immediately

Stroke Syndromes by Territory

Territory	Key Features
MCA (anterior circulation)	Contralateral hemiplegia (arm > leg), hemisensory loss, aphasia (dominant), neglect (non-dominant), gaze deviation toward lesion
ACA	Contralateral leg weakness > arm, personality change, incontinence
PCA	Contralateral homonymous hemianopia, thalamic involvement (sensory loss), alexia without agraphia
Basilar artery	Locked-in syndrome, coma, cranial nerve palsies, cerebellar signs, "crossed" deficits
PICA (lateral medullary - Wallenberg)	Ipsilateral facial + contralateral body sensory loss, ipsilateral Horner's, dysphagia, vertigo, hiccups
Lacunar syndromes	Pure motor hemiplegia, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand

NIHSS (National Institutes of Health Stroke Scale)

Scores 0-42; higher = more severe
0-5 = minor; 6-15 = moderate; 16-20 = moderate-severe; >20 = severe
2026 update: NIHSS no longer sole gatekeeper for IVT - see treatment section

5. DIAGNOSIS

Prehospital

Cincinnati Prehospital Stroke Scale (CPSS): face, arm, speech - 1 abnormal = 72% stroke likelihood
Activate stroke protocol immediately
2026 guideline: Direct transport to endovascular thrombectomy (EVT)-capable hospital preferred when rapid interhospital transfer is not available

ED Assessment - Immediate (<10 minutes on arrival)

STAT labs:

CBC, PT/INR, aPTT, blood glucose (hypoglycemia mimics stroke!)
BMP, troponin, ECG (cardiac source, AF)
Blood type and screen

STAT imaging:

Imaging	Role
Non-contrast CT (NCCT)	First-line - rule out hemorrhage; very fast
CT Angiography (CTA)	Large vessel occlusion (LVO) - essential for EVT decision
CT Perfusion (CTP)	Penumbra assessment for extended window (4.5-24h)
MRI DWI	Most sensitive for early ischemia; DWI-FLAIR mismatch for wake-up stroke
MR Angiography	Alternative to CTA for vessel imaging

ASPECTS Score (Alberta Stroke Program Early CT Score)

10-point scale assessing early ischemic changes on CT in MCA territory
10 = no ischemia; 0 = severe ischemia throughout MCA territory
2026 update: EVT now Class 1 even for ASPECTS 3-5 (previously controversial)

6. ACUTE MANAGEMENT - AHA/ASA 2026 GUIDELINE

Immediate General Care

Parameter	Target	Notes
O₂ saturation	>94%	Supplemental O₂ only if hypoxic
Temperature	Normothermia	Treat fever aggressively (antipyretics)
Blood glucose	140-180 mg/dL	Do NOT target 80-130 mg/dL (2026 update)
Hypoglycemia	Treat if <60 mg/dL	IV dextrose immediately
IV fluids	Normal saline (isotonic)	Avoid hypotonic (worsens cerebral edema)
NPO	Until dysphagia screening	New 2026 emphasis on formal dysphagia assessment before any oral intake

Step 1: Hemorrhage Excluded on CT → Decision for Reperfusion

REPERFUSION THERAPY

A. IV Thrombolysis (IVT)

🆕 KEY 2026 UPDATE: Disabling vs Non-Disabling - Primary Decision Framework

The fundamental question is no longer "What is the NIHSS score?" but "Is this deficit disabling for this patient?"

Deficit Type	Action
Disabling (even if NIHSS 0-5)	Give IVT - Class 1
Non-disabling (patient can function at baseline)	Do NOT give IVT - give DAPT instead

Examples of disabling with low NIHSS: dominant-hand weakness preventing work, visual field loss preventing driving, aphasia preventing communication.

🆕 Drug Choice: Tenecteplase NOW Class 1 (equal to alteplase)

Drug	Dose	Administration	Class (2026)
Tenecteplase (TNK)	0.25 mg/kg IV (max 25 mg)	Single bolus - push and go	Class 1
Alteplase (tPA)	0.9 mg/kg IV (max 90 mg)	10% bolus over 1 min + 90% infusion over 60 min	Class 1

Tenecteplase advantages (2026 rationale):

Single IV bolus - much simpler to administer

Enables immediate transfer after injection ("push and go")

Non-inferior efficacy and safety vs alteplase (multiple RCTs including NOR-TEST 2, AcT trial)

Many centers are already shifting to tenecteplase

Time Windows for IVT

Window	Recommendation	Class
0-4.5 hours (standard)	IVT for disabling deficit, no contraindications	Class 1
🆕 4.5-9 hours / wake-up stroke	IVT may be reasonable if CTP or DWI-FLAIR mismatch shows salvageable brain	Class 2a (NEW)
🆕 Up to 24 hours (select patients)	IVT for extended window when advanced imaging confirms penumbra	Class 2b

The extended 4.5-9h window is based on the EXTEND, ECASS-4, and WAKE-UP trials.

Pre-IVT Blood Pressure Target

BP must be <185/110 mmHg before giving IVT
Use labetalol, nicardipine, or clevidipine to lower if needed
Post-IVT target: maintain BP <180/105 mmHg for 24 hours

IVT Absolute Contraindications (2026 - key changes)

Contraindication	2026 Status
Intracranial hemorrhage on CT	Absolute contraindication (unchanged)
BP >185/110 refractory to treatment	Absolute
Recent major surgery (<14 days)	Absolute
INR >1.7 on warfarin	Absolute
DOAC taken within 48 hours (standard dose)	Absolute
Blood glucose <50 mg/dL	Absolute
🆕 Non-disabling deficit	New - do not give IVT
🆕 Prior ICH	Reclassified as relative contraindication (case-by-case)

BP Management AFTER IVT (2026)

Target <180/105 mmHg for first 24 hours
🆕 ESO 2025 update: Intensive lowering to <140 mmHg after reperfusion is NOT recommended (Class 3 - harm)

B. Endovascular Thrombectomy (EVT / Mechanical Thrombectomy)

Standard Window: 0-24 Hours (LVO)

Core eligibility criteria (2026):

Large vessel occlusion (LVO) confirmed on CTA (ICA, M1, M2 MCA, basilar)
NIHSS ≥6 (for anterior circulation)
Pre-stroke mRS ≤2 (functionally independent before stroke)
Within 24 hours of last known well

🆕 2026 EVT Updates

Update	Details	Class
Expanded core size	EVT now recommended for ASPECTS 3-5 (large ischemic core)	Class 1 (expanded from previous Class 2b)
ASPECTS 0-2	EVT may be considered in selected patients	Class 2a (new)
Basilar artery occlusion	EVT up to 24 hours if NIHSS ≥10	Class 1
Direct to EVT-capable center	Recommended when interhospital transfer is slow	Class 1
Bridging IVT + EVT	Give IVT if eligible, then proceed immediately to EVT without waiting	Class 1
Posterior circulation	EVT supported with new evidence from ATTENTION and BAOCHE trials	Class 1

🆕 Pediatric Stroke (NEW section in 2026 guidelines)

IVT may be considered in children with AIS (Class 2b)
EVT reasonable for children ≥6 years with LVO (Class 2a)
Previously had minimal guidance for pediatric patients

7. BLOOD PRESSURE MANAGEMENT IN ACUTE STROKE

Pre-Thrombolysis/Thrombectomy

Must be <185/110 before IVT

After IVT (Post-thrombolysis 24h)

<180/105 mmHg

After Successful Reperfusion (EVT or IVT)

🆕 ESO 2025 / AHA 2026: Intensive lowering to <140 mmHg is NOT recommended - associated with worse outcomes
Allow permissive hypertension (up to 180/105 is acceptable)

No Reperfusion Therapy (conservative management)

Do NOT lower BP unless >220/120 mmHg (or hypertensive emergency features)
Permissive hypertension maintained for 24-48h to preserve penumbral flow
Exception: lower BP if concomitant ACS, aortic dissection, hypertensive encephalopathy

ICH

Target SBP 130-140 mmHg within 1 hour of presentation (based on INTERACT3 trial)

8. SECONDARY PREVENTION

Antiplatelet Therapy

Scenario	Regimen	Duration
Minor stroke (NIHSS ≤3) / high-risk TIA (ABCD2 ≥4)	DAPT: Aspirin 100 mg + Clopidogrel 75 mg	21 days (POINT/CHANCE trial) then single agent
Post-EVT (no thrombolysis)	DAPT for 21 days (Class 1, LOE A)	21 days
Routine post-stroke	Aspirin 100 mg daily	Long-term
Post-EVT with acute stenting	DAPT for 30-90 days (Class 2a)
🆕 Non-disabling stroke (no IVT given)	DAPT preferred over IVT (2026)	21 days
Aspirin allergy	Clopidogrel 75 mg daily	Long-term

Anticoagulation

Indication	Agent	Notes
AF-related cardioembolic stroke	DOAC (preferred) or warfarin	Start within 2-14 days depending on infarct size
Mechanical heart valve	Warfarin (INR 2.5-3.5)	DOACs contraindicated
Venous sinus thrombosis	Heparin → warfarin/DOAC
Cervical artery dissection	Antiplatelet OR anticoagulation	Equivalent efficacy (CADISS trial)
PFO + cryptogenic stroke	Consider closure (ESO 2024 guideline - preferred over medical therapy in selected patients)

Lipid Management (ILEP 2026 Consensus)

Target LDL-C < 1.4 mmol/L (<55 mg/dL) for secondary prevention
High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) first-line
Add ezetimibe if target not reached
Add PCSK9 inhibitor (inclisiran/alirocumab/evolocumab) if still not at goal

Blood Pressure (Long-term Secondary Prevention)

Target <130/80 mmHg
Start/restart antihypertensives within 24-48h if hemodynamically stable after acute phase

Glucose & Diabetes

HbA1c target < 7% for secondary stroke prevention
GLP-1 agonists / SGLT2 inhibitors preferred in diabetic patients with atherosclerotic disease

9. DYSPHAGIA MANAGEMENT (🆕 2026 Emphasis)

Formal dysphagia screening before any oral intake is now strongly recommended (2026 update)
Failed screening → NPO, speech therapy evaluation, consider NGT
Early dysphagia management reduces aspiration pneumonia - a major cause of post-stroke death

10. STROKE UNIT CARE & MONITORING (24-48 Hours)

Parameter	Monitor For
Neurological status	NIHSS q1-2h; watch for early deterioration
BP	Per reperfusion status targets above
Cardiac monitoring	24-48h continuous ECG for AF detection
Temperature	Hyperthermia worsens outcomes - treat aggressively
O₂ saturation	>94%
Glucose	140-180 mg/dL
Swallowing	Formal assessment before oral intake
DVT prophylaxis	Pneumatic compression stockings from admission

11. HEMORRHAGIC STROKE (ICH) - KEY POINTS

Immediate BP control: SBP to 130-140 mmHg within 1 hour (INTERACT3)
Reverse anticoagulation immediately:
- Warfarin → 4-factor PCC + Vitamin K IV
- Dabigatran → Idarucizumab (Praxbind)
- Factor Xa inhibitors → Andexanet alfa
Neurosurgery consultation: for cerebellar ICH >3 cm, hydrocephalus, herniation
External ventricular drain (EVD) for obstructive hydrocephalus
Do NOT give steroids (worsen outcomes in ICH)

12. SUMMARY TABLE: 2026 KEY CHANGES AT A GLANCE

Topic	Old (2018/2019)	New (2026)
Thrombolytic choice	Alteplase preferred	Tenecteplase = Alteplase (both Class 1)
IVT decision trigger	NIHSS score	Disabling vs non-disabling deficit
IVT window	0-4.5h standard	0-4.5h standard; 4.5-9h with imaging mismatch (Class 2a)
Non-disabling stroke	IVT not recommended	DAPT preferred (explicitly stated)
EVT core size	ASPECTS ≥6 preferred	Class 1 for ASPECTS 3-5; Class 2a for 0-2
Basilar occlusion EVT	Limited window guidance	EVT up to 24h if NIHSS ≥10 (Class 1)
Post-reperfusion BP	Not clearly defined	Intensive <140 mmHg NOT recommended (Class 3)
Glucose target	140-180 mg/dL	140-180 mg/dL confirmed; 80-130 actively discouraged
Pediatric stroke	Minimal guidance	Dedicated section: IVT (Class 2b), EVT ≥6 yrs (Class 2a)
Dysphagia	Screening recommended	Formal assessment before ANY oral intake - stronger emphasis
PFO closure	Uncertain	ESO 2024: PFO closure preferred over medical therapy in selected cryptogenic stroke
Transport	Nearest stroke center	Direct to EVT-capable center when transfer systems inadequate

Sources:

2026 AHA/ASA Guideline (Prabhakaran et al. Stroke, Jan 26, 2026. PMID 41582814)
ESO 2025 BP Management Update (Sandset et al. Eur Stroke J, May 2026. PMID 42095756)
ESO 2024 PFO Guidelines (PMID 38752755)
ILEP 2026 Lipid-Stroke Consensus (PMID 41249078)
Rosen's Emergency Medicine | Bradley & Daroff's Neurology in Clinical PracticeThis is the most current stroke note available, built directly from the brand-new AHA/ASA 2026 guideline (published January 26, 2026 - just 5 months ago). Here are the most important takeaways from the update:

The 5 Biggest 2026 Changes to Remember

Tenecteplase = Alteplase (Class 1) - Single bolus injection makes it much faster and easier to use. Many centers are already switching.
"Disabling vs Non-disabling" replaces NIHSS as the IVT trigger - A patient with NIHSS 2 but dominant-hand weakness that prevents their job SHOULD get IVT. A patient with NIHSS 4 but no functional impact should NOT get IVT (give DAPT instead).
Extended IVT window to 4.5-9 hours with CTP or DWI-FLAIR mismatch on imaging - important for rural areas and wake-up strokes.
EVT for large cores (ASPECTS 3-5) is now Class 1 - previously was controversial. More patients now qualify for thrombectomy even with larger infarcts on arrival.
Don't aggressively lower BP after reperfusion - targeting <140 mmHg post-reperfusion was found to harm outcomes. Permissive hypertension up to 180/105 is acceptable.

Different triage system for emergency physician

Searching sources...

Finding Sources

Searching the Web

emergency department triage systems comparison ESI Manchester ATS CTAS START MCI 2024 2025

Finding Sources

Searching the Web

START triage SALT triage mass casualty incident MCI system categories 2025

Reading File

I now have comprehensive content. Here is the complete triage reference note:

Triage Systems for the Emergency Physician - Complete Reference

Triage derives from the French "trier" (to sort). The goal differs fundamentally between routine ED triage (identify the sickest individual) and disaster/MCI triage (do the most good for the most people).

PART 1: ED (ROUTINE) TRIAGE SYSTEMS

Five major 5-level systems are used worldwide. 5-level systems are superior to 3-level systems in both validity and reliability.

1. Emergency Severity Index (ESI) 🇺🇸

Used in: United States (most widely used), many international EDs Basis: Acuity + anticipated resource utilization Levels: 5

Level	Category	Color	Criteria	Target Time to Physician
1	Resuscitation	Red	Requires immediate life-saving intervention (intubation, defibrillation, CPR)	Immediate
2	Emergent	Orange	High-risk situation; lethargic/disoriented; severe pain/distress; dangerous vital signs	<15 min
3	Urgent	Yellow	Stable vitals but needs multiple resources (labs + imaging + IV)	<30 min
4	Less Urgent	Green	Needs one resource only (one lab OR one X-ray)	<60 min
5	Non-Urgent	Blue	Needs no resources - history + exam only	<120 min

ESI Decision Algorithm:

Step 1: Does the patient need IMMEDIATE life-saving intervention? → Level 1
Step 2: Is this a HIGH-RISK situation / confused / severe distress? → Level 2
Step 3: How many RESOURCES will this patient need?
         ≥2 resources → Level 3 (also check vital signs - abnormals bump to Level 2)
         1 resource → Level 4
         0 resources → Level 5

Vital sign thresholds that bump Level 3 → Level 2:

HR >100 or <50 | RR >20 | SpO₂ <92% | Temperature >38.5°C | Altered mentation

Pros: Simple, resource-based, widely validated, used for all ages (with pediatric modification) Cons: "Resources" subjective; poor inter-rater reliability across countries

2. Manchester Triage System (MTS) 🇬🇧

Used in: UK, Europe, Netherlands, Brazil Basis: Presenting complaint → flowchart → discriminators Levels: 5

Level	Category	Color	Target Time
1	Immediate	Red	Immediate (0 min)
2	Very Urgent	Orange	10 minutes
3	Urgent	Yellow	60 minutes
4	Standard	Green	120 minutes
5	Non-Urgent	Blue	240 minutes

How it works:

Select the presenting complaint flowchart (52 flowcharts e.g., chest pain, headache, breathing difficulty)
Work through discriminators in priority order (e.g., airway compromise → shock → extreme pain)
Assign level based on the first positive discriminator encountered

Key discriminators: Life threat, airway compromise, haemodynamic abnormality, level of consciousness, temperature, pain score

Pros: Structured, symptom-specific, systematic flowcharts, widely used in Europe Cons: Slower (~3-5 min per patient); less sensitive in elderly with atypical presentations; limited sensitivity for frail patients (2025 PLOS ONE study)

3. Canadian Triage and Acuity Scale (CTAS) 🇨🇦

Used in: Canada, some Asian and Middle Eastern countries Basis: Chief complaint + modifiers + vital signs Levels: 5

Level	Category	Color	Target Time to Physician	Reassessment
1	Resuscitation	Blue/Red	Immediate	Continuous
2	Emergent	Red/Orange	15 minutes	Every 15 min
3	Urgent	Yellow	30 minutes	Every 30 min
4	Less Urgent	Green	60 minutes	Every 60 min
5	Non-Urgent	White	120 minutes	Every 120 min

Unique features:

Only system with mandatory reassessment intervals at each level
Uses modifiers: first-order (chief complaint-based) and second-order (pain, mechanism of injury)
Pediatric version: PaedsCTAS (accounts for age-adjusted vitals, pediatric-specific presentations)
Highest reliability among all systems (κ = 0.7-0.95)

Pros: Very reliable, reassessment built in, robust pediatric version, well-validated Cons: Complex, takes 5-10 minutes to complete properly; requires training

4. Australasian Triage Scale (ATS) 🇦🇺

Used in: Australia, New Zealand Basis: Clinical urgency - time to treatment Levels: 5

Level	Category	Color	Max Time to Treatment	Duration of Assessment
1	Immediately Life-Threatening	Red	Immediate	Continuous
2	Imminently Life-Threatening	Orange	10 minutes	Every 10 min
3	Potentially Life-Threatening	Yellow	30 minutes	Every 30 min
4	Potentially Serious	Green	60 minutes	Every 60 min
5	Less Urgent	Blue	120 minutes	Every 120 min

Unique features:

Specifies initial assessment time (not just time to physician)
Explicitly states duration of each assessment
Includes mental health and social triage criteria

Pros: Time-based, clear, established nationally Cons: Moderate reliability (κ = 0.3-0.6); less resource-oriented

5. South African Triage Scale (SATS) 🇿🇦

Used in: South Africa, sub-Saharan Africa, resource-limited settings Basis: Triage Early Warning Score (TEWS) + presenting complaint discriminators Levels: 5

Level	Category	Color	Action
1	Emergency	Red	Immediate
2	Very Urgent	Orange	Within 10 min
3	Urgent	Yellow	Within 1 hour
4	Routine	Green	Within 4 hours
5	Not Urgent	Blue	Within 8 hours

TEWS scoring: Walking ability + respiratory rate + oxygen saturation + temperature + heart rate + systolic BP + AVPU

Unique: Designed for resource-limited settings; incorporates mobility assessment as a key first step

HEAD-TO-HEAD COMPARISON TABLE

Feature	ESI	MTS	CTAS	ATS	SATS
Origin	USA	UK	Canada	Australia	South Africa
Basis	Acuity + resources	Symptom flowcharts	Complaint + modifiers	Clinical urgency	TEWS + complaint
Levels	5	5	5	5	5
Time to complete	1-2 min	3-5 min	5-10 min	2-3 min	2-3 min
Mandatory reassessment	No	No	Yes	No	No
Pediatric version	Yes (ESI-Peds)	Yes (PaedsMTS)	Yes (PaedsCTAS)	Yes	Yes
Reliability (κ)	0.7-0.9	0.3-0.6	0.7-0.95	0.3-0.6	0.7
Best for	US EDs, resource prediction	European EDs, symptom-driven	High-reliability, training	Australian setting	Low-resource settings
Weakness	Resources subjective	Slow, poor for elderly/atypical	Complex, time-consuming	Moderate reliability	Limited international validation

No single triage system has proven clearly superior to the others - selection depends on setting, training, and local validation.

PART 2: MASS CASUALTY INCIDENT (MCI) TRIAGE SYSTEMS

Goal shifts from individual care to utilitarian: greatest good for greatest number. MCI defined as ≥5 patients overwhelming local resources.

Universal MCI Triage Color Categories

Color	Category	Meaning
🔴 Red	Immediate	Life-threatening; needs treatment NOW to survive
🟡 Yellow	Delayed	Serious but stable; can wait
🟢 Green	Minimal/Minor	"Walking wounded"; minor injuries
⚫ Black	Expectant/Dead	Injuries incompatible with survival given resources; or no signs of life
⚫ Gray	Expectant (SALT only)	Expected to die despite maximal intervention

1. START (Simple Triage And Rapid Treatment) 🇺🇸

Used: Prehospital/field triage, adults Speed: 30-60 seconds per patient Assessment: RPM - Respirations, Perfusion, Mental status

Algorithm:

Can the patient WALK?
    YES → GREEN (minimal/walking wounded)
    NO ↓
Is patient BREATHING?
    NO → Open airway → still not breathing? → BLACK (deceased)
         Breathing after opening? → RED (immediate)
    YES ↓
Respiratory rate?
    >30/min → RED (immediate)
    <10/min → RED (immediate)
    10-29/min ↓
Perfusion: Radial pulse or capillary refill >2 sec?
    No pulse / CRT >2 sec → RED (immediate) + hemorrhage control
    Pulse present / CRT ≤2 sec ↓
Mental status: Can follow simple commands?
    NO → RED (immediate)
    YES → YELLOW (delayed)

Key rule: During START, only two interventions allowed:

Open airway (head-tilt/chin-lift)
Direct pressure on obvious external hemorrhage

Pros: Fast, simple, validated in real MCI (2002 Placentia Linda train crash - 100% sensitivity for RED category) Cons: Requires capillary refill or respiratory rate (may be inaccurate in field); some overtriage

2. SALT (Sort, Assess, Lifesaving interventions, Treatment/Transport) 🇺🇸

Used: US national standard (CDC-recommended), prehospital + hospital Developed: 2011 by multidisciplinary consensus (Model Uniform Core Criteria)

Two-phase approach:

Phase 1 - SORT (global):

"If you can hear me and can walk, move to [safe area]" → GREEN
Assess remaining in priority: Still > Waving > Those who walked but couldn't relocate

Phase 2 - ASSESS (individual, one-by-one):

Assessment	Finding	Category
No signs of life	No breathing, no pulse	BLACK (dead)
Signs of life present	→ Perform brief lifesaving interventions if possible (control hemorrhage, open airway, give antidote)	↓
After interventions: Likely to survive?	Cannot follow commands + no peripheral pulse + poor breathing	GRAY (expectant)
Obeys commands OR has peripheral pulse OR normal breathing	→	RED (immediate)
Significant injury, not immediate	Can wait	YELLOW (delayed)
Minor / no injury	Ambulatory	GREEN (minimal)

Key difference from START: SALT adds GRAY category (expectant - will likely die) separate from BLACK (already dead) - eliminates ambiguity about dying but not yet dead patients

Pros: More precise categorization, all-hazards approach (trauma/medical/chemical/radiological), reduces undertriage by 9% vs START Cons: Slightly more complex; less studied in real disasters than START

Rosen's Emergency Medicine recommends START until more evidence on SALT accumulates.

3. JumpSTART (Pediatric MCI Triage)

Used: Children in MCI settings Modification of START with pediatric-specific criteria:

Step	START (Adults)	JumpSTART (Children)
Apneic patient	→ BLACK	→ Attempt 5 rescue breaths first → if still apneic → BLACK
Resp rate normal	10-29/min	15-45/min
Mental status	Follow commands	AVPU scale (Alert, Voice, Pain, Unresponsive)

4. CareFlight Triage

Used: Australia, some prehospital systems Steps: Walk → Obeys commands → Pulse → Respiratory effort

Performed best overall across all ages in multi-tool evaluation
Simpler than JumpSTART for pediatric victims

5. RAMP (Rapid Assessment of Mentation and Pulse)

Used: Emerging system, military and tactical medicine Basis: Mental status + pulse only

Faster than START (assesses only 2 parameters)
Results largely similar to START in final categorization
Suitable when time is extremely limited

PART 3: SPECIAL SITUATIONS IN TRIAGE

CBRN / Hazmat Triage

Decontamination BEFORE standard triage
Antidote administration (e.g., atropine for organophosphate) is a lifesaving intervention during SALT
PPE for triage personnel mandatory

Pediatric Considerations (Routine ED)

All major ED systems have pediatric versions (ESI, CTAS, MTS, ATS)
No single pediatric ED triage system proven superior
Pediatric Triage Tape (PTT): Length-based criteria for infants/toddlers in MCI settings

Geriatric Triage

Both ESI and MTS show limited sensitivity in elderly patients with atypical presentations (PLOS ONE, 2025)
ESI performs better than MTS for discriminating urgency in older adults
Current consensus: triage systems need revision to account for age-related vulnerability and non-specific presentations

QUICK REFERENCE SUMMARY

ROUTINE ED TRIAGE (most to least reliable):
CTAS > ESI > MTS > ATS > SATS

MCI/DISASTER TRIAGE:
Adults: START (most validated) or SALT (US national standard)
Children: JumpSTART (pediatric modification of START)

KEY PRINCIPLE DIFFERENCES:
ED triage   = save the sickest INDIVIDUAL
MCI triage  = save the MOST people with available resources

Different triage system for emergency physician

It looks like this is the same question you just asked — I provided a full detailed answer covering all major triage systems just a few minutes ago.

Here's a quick recap of what was covered:

Part 1 - Routine ED Triage Systems (5-level):

ESI (USA) - acuity + resource utilization
MTS / Manchester (UK/Europe) - symptom flowcharts
CTAS (Canada) - most reliable, mandatory reassessment intervals
ATS (Australia) - time-based, nationally mandated
SATS (South Africa) - TEWS scoring, resource-limited settings

Part 2 - Mass Casualty / MCI Triage:

START - adult field triage (RPM assessment, 30-60 sec/patient)
SALT - US national standard (Sort→Assess→Lifesaving interventions), adds Gray category
JumpSTART - pediatric modification of START
CareFlight - best overall performance in pediatric evaluations
RAMP - rapid 2-parameter assessment (mentation + pulse)

Part 3 - Special considerations:

CBRN/Hazmat triage
Geriatric triage limitations
Pediatric ED triage systems

Scroll up to see the full detailed note with algorithms, color categories, time targets, comparison tables, and decision flowcharts. Let me know if you'd like me to expand on any specific system or add anything!

Generate a pocket guide PDF for ESI vs CTAS decision-making

Reading File

Running Command

ls -la /home/daytona/workspace/ 2>/dev/null || echo "workspace does not exist"

Running Command

mkdir -p /home/daytona/workspace/triage-guide && python3 -c "import reportlab; print('reportlab ok')"

Writing File

~/triage-guide/generate_pocket_guide.py

from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.units import mm, cm
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_RIGHT
from reportlab.platypus import (
    SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
    HRFlowable, KeepTogether
)
from reportlab.platypus.flowables import HRFlowable
from reportlab.lib.colors import HexColor

# ── Colour palette ──────────────────────────────────────────────────────────
NAVY      = HexColor('#0D1B4B')
TEAL      = HexColor('#0077A8')
ORANGE    = HexColor('#E05A00')
LIGHT_BG  = HexColor('#F0F4FA')
WHITE     = colors.white

# Triage level colours
RED       = HexColor('#C62828')
ORANGE_T  = HexColor('#E65100')
YELLOW_T  = HexColor('#F9A825')
GREEN_T   = HexColor('#2E7D32')
BLUE_T    = HexColor('#1565C0')

L_RED     = HexColor('#FFCDD2')
L_ORANGE  = HexColor('#FFE0B2')
L_YELLOW  = HexColor('#FFF9C4')
L_GREEN   = HexColor('#C8E6C9')
L_BLUE    = HexColor('#BBDEFB')

# ── Document setup ──────────────────────────────────────────────────────────
OUTPUT = '/home/daytona/workspace/triage-guide/ESI_vs_CTAS_Pocket_Guide.pdf'
doc = SimpleDocTemplate(
    OUTPUT,
    pagesize=A4,
    leftMargin=14*mm, rightMargin=14*mm,
    topMargin=14*mm,  bottomMargin=14*mm,
    title='ESI vs CTAS Pocket Guide',
    author='Emergency Medicine Reference'
)

# ── Styles ───────────────────────────────────────────────────────────────────
styles = getSampleStyleSheet()

def S(name, **kw):
    return ParagraphStyle(name, **kw)

title_style = S('Title2',
    fontName='Helvetica-Bold', fontSize=18,
    textColor=WHITE, alignment=TA_CENTER, leading=22)

subtitle_style = S('Sub',
    fontName='Helvetica', fontSize=9,
    textColor=HexColor('#BBDEFB'), alignment=TA_CENTER, leading=12)

section_style = S('Section',
    fontName='Helvetica-Bold', fontSize=11,
    textColor=WHITE, alignment=TA_CENTER, leading=14)

body_style = S('Body2',
    fontName='Helvetica', fontSize=8.5,
    textColor=HexColor('#1A1A2E'), leading=12)

small_style = S('Small',
    fontName='Helvetica', fontSize=7.5,
    textColor=HexColor('#333355'), leading=10)

bold_small = S('BoldSmall',
    fontName='Helvetica-Bold', fontSize=8,
    textColor=HexColor('#1A1A2E'), leading=11)

note_style = S('Note',
    fontName='Helvetica-Oblique', fontSize=7.5,
    textColor=HexColor('#444466'), leading=10)

cell_style = S('Cell',
    fontName='Helvetica', fontSize=8,
    textColor=HexColor('#1A1A2E'), leading=11, alignment=TA_LEFT)

cell_bold = S('CellBold',
    fontName='Helvetica-Bold', fontSize=8.5,
    textColor=HexColor('#1A1A2E'), leading=11, alignment=TA_LEFT)

hdr_style = S('Hdr',
    fontName='Helvetica-Bold', fontSize=9,
    textColor=WHITE, alignment=TA_CENTER, leading=12)

# ── Helper to build a coloured header banner ─────────────────────────────────
def banner(text, bg=NAVY, text_style=None):
    ts = text_style or section_style
    tbl = Table([[Paragraph(text, ts)]], colWidths=[182*mm])
    tbl.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), bg),
        ('TOPPADDING',    (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
        ('LEFTPADDING',   (0,0), (-1,-1), 8),
        ('RIGHTPADDING',  (0,0), (-1,-1), 8),
        ('ROUNDEDCORNERS', [4,4,4,4]),
    ]))
    return tbl

# ── Title block ───────────────────────────────────────────────────────────────
title_tbl = Table(
    [[Paragraph('ESI vs CTAS', title_style)],
     [Paragraph('Emergency Triage Pocket Guide  |  For Emergency Physicians & Nurses', subtitle_style)]],
    colWidths=[182*mm]
)
title_tbl.setStyle(TableStyle([
    ('BACKGROUND', (0,0), (-1,-1), NAVY),
    ('TOPPADDING',    (0,0), (-1,-1), 8),
    ('BOTTOMPADDING', (0,0), (-1,-1), 8),
    ('LEFTPADDING',   (0,0), (-1,-1), 10),
    ('RIGHTPADDING',  (0,0), (-1,-1), 10),
]))

# ── ESI decision algorithm table ──────────────────────────────────────────────
esi_algo = [
    [Paragraph('<b>Step</b>', hdr_style),
     Paragraph('<b>Question</b>', hdr_style),
     Paragraph('<b>Answer</b>', hdr_style),
     Paragraph('<b>Level</b>', hdr_style)],
    [Paragraph('1', cell_bold),
     Paragraph('Immediate life-saving intervention needed?', cell_style),
     Paragraph('YES', cell_style),
     Paragraph('Level 1 🔴', cell_bold)],
    [Paragraph('2', cell_bold),
     Paragraph('High-risk / confused / severe distress / dangerous vitals?', cell_style),
     Paragraph('YES', cell_style),
     Paragraph('Level 2 🟠', cell_bold)],
    [Paragraph('3', cell_bold),
     Paragraph('How many RESOURCES needed?', cell_style),
     Paragraph('≥ 2 resources\n1 resource\n0 resources', cell_style),
     Paragraph('Level 3 🟡\nLevel 4 🟢\nLevel 5 🔵', cell_bold)],
    [Paragraph('3a', cell_bold),
     Paragraph('If Level 3: Are vitals dangerous?', cell_style),
     Paragraph('YES → upgrade', cell_style),
     Paragraph('Level 2 🟠', cell_bold)],
]

esi_algo_tbl = Table(esi_algo, colWidths=[13*mm, 72*mm, 45*mm, 30*mm])
esi_algo_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (-1,0), NAVY),
    ('BACKGROUND',    (0,1), (-1,1), L_RED),
    ('BACKGROUND',    (0,2), (-1,2), L_ORANGE),
    ('BACKGROUND',    (0,3), (-1,3), L_YELLOW),
    ('BACKGROUND',    (0,4), (-1,4), L_ORANGE),
    ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
    ('FONTSIZE',      (0,0), (-1,-1), 8),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
    ('TOPPADDING',    (0,0), (-1,-1), 4),
    ('BOTTOMPADDING', (0,0), (-1,-1), 4),
    ('LEFTPADDING',   (0,0), (-1,-1), 5),
    ('RIGHTPADDING',  (0,0), (-1,-1), 5),
]))

# ── ESI Vital sign danger zone table ─────────────────────────────────────────
vitals_data = [
    [Paragraph('<b>Parameter</b>', hdr_style),
     Paragraph('<b>Age <3 mo</b>', hdr_style),
     Paragraph('<b>3 mo–3 yr</b>', hdr_style),
     Paragraph('<b>3–8 yr</b>', hdr_style),
     Paragraph('<b>>8 yr / Adult</b>', hdr_style)],
    ['HR > (bpm)', '>180', '>160', '>140', '>100'],
    ['HR < (bpm)', '<50',  '<50',  '<50',  '<50'],
    ['RR > (bpm)', '>50',  '>40',  '>30',  '>20'],
    ['SpO₂ <',     '<92%', '<92%', '<92%', '<92%'],
    ['Temp °C >',  '>38',  '>38.5','—',    '>38.5'],
]
vitals_tbl = Table(vitals_data, colWidths=[28*mm, 28*mm, 28*mm, 28*mm, 40*mm])
vitals_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (-1,0), TEAL),
    ('BACKGROUND',    (0,1), (-1,1), HexColor('#F8F8FF')),
    ('BACKGROUND',    (0,2), (-1,2), HexColor('#F0F0FF')),
    ('BACKGROUND',    (0,3), (-1,3), HexColor('#F8F8FF')),
    ('BACKGROUND',    (0,4), (-1,4), HexColor('#F0F0FF')),
    ('BACKGROUND',    (0,5), (-1,5), HexColor('#F8F8FF')),
    ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
    ('FONTNAME',      (0,1), (0,-1), 'Helvetica-Bold'),
    ('FONTSIZE',      (0,0), (-1,-1), 7.5),
    ('ALIGN',         (0,0), (-1,-1), 'CENTER'),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
    ('TOPPADDING',    (0,0), (-1,-1), 3),
    ('BOTTOMPADDING', (0,0), (-1,-1), 3),
]))

# ── CTAS decision table ───────────────────────────────────────────────────────
ctas_data = [
    [Paragraph('<b>Level</b>', hdr_style),
     Paragraph('<b>Category</b>', hdr_style),
     Paragraph('<b>Colour</b>', hdr_style),
     Paragraph('<b>Time to MD</b>', hdr_style),
     Paragraph('<b>Reassess</b>', hdr_style),
     Paragraph('<b>Examples</b>', hdr_style)],
    ['1', 'Resuscitation',  '🔴 Red',    'Immediate',  'Continuous',
     'Cardiac arrest, apnoea, RSI needed'],
    ['2', 'Emergent',       '🟠 Orange', '≤15 min',    'q15 min',
     'STEMI, stroke, sepsis, major trauma'],
    ['3', 'Urgent',         '🟡 Yellow', '≤30 min',    'q30 min',
     'Moderate pain, stable GI bleed, seizure (postictal)'],
    ['4', 'Less Urgent',    '🟢 Green',  '≤60 min',    'q60 min',
     'Minor injury, sore throat, UTI symptoms'],
    ['5', 'Non-Urgent',     '🔵 Blue',   '≤120 min',   'q120 min',
     'Prescription refill, rash, well-child concern'],
]
ctas_tbl = Table(ctas_data, colWidths=[10*mm, 28*mm, 18*mm, 22*mm, 20*mm, 64*mm])
ctas_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (-1,0), NAVY),
    ('BACKGROUND',    (0,1), (-1,1), L_RED),
    ('BACKGROUND',    (0,2), (-1,2), L_ORANGE),
    ('BACKGROUND',    (0,3), (-1,3), L_YELLOW),
    ('BACKGROUND',    (0,4), (-1,4), L_GREEN),
    ('BACKGROUND',    (0,5), (-1,5), L_BLUE),
    ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
    ('FONTNAME',      (0,1), (0,-1), 'Helvetica-Bold'),
    ('FONTSIZE',      (0,0), (-1,-1), 7.5),
    ('ALIGN',         (1,0), (4,-1), 'CENTER'),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
    ('TOPPADDING',    (0,0), (-1,-1), 4),
    ('BOTTOMPADDING', (0,0), (-1,-1), 4),
    ('LEFTPADDING',   (0,0), (-1,-1), 4),
    ('RIGHTPADDING',  (0,0), (-1,-1), 4),
]))

# ── ESI Level detailed table ──────────────────────────────────────────────────
esi_levels = [
    [Paragraph('<b>Level</b>', hdr_style),
     Paragraph('<b>Category</b>', hdr_style),
     Paragraph('<b>Basis for Decision</b>', hdr_style),
     Paragraph('<b>Wait Time</b>', hdr_style),
     Paragraph('<b>Clinical Examples</b>', hdr_style)],
    ['1', 'Resuscitation',
     'Immediate life-saving intervention required NOW',
     'Immediate',
     'Intubation, cardioversion, CPR, massive haemorrhage'],
    ['2', 'Emergent',
     'High-risk; confused/lethargic; severe pain/distress; danger vitals',
     '<15 min',
     'STEMI, anaphylaxis, active seizure, severe dyspnoea, suicidal'],
    ['3', 'Urgent',
     '≥2 resources needed; vitals normal or mildly abnormal',
     '<30 min',
     'Abdominal pain (labs + CT), moderate asthma (neb + CXR)'],
    ['4', 'Less Urgent',
     'Only 1 resource needed; no distress',
     '<60 min',
     'Ankle sprain (X-ray only), simple laceration (repair only)'],
    ['5', 'Non-Urgent',
     '0 resources; history + exam only',
     '<120 min',
     'Prescription refill, cold symptoms, well-controlled chronic disease'],
]
esi_levels_tbl = Table(esi_levels, colWidths=[10*mm, 25*mm, 55*mm, 20*mm, 60*mm])
esi_levels_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (-1,0), NAVY),
    ('BACKGROUND',    (0,1), (-1,1), L_RED),
    ('BACKGROUND',    (0,2), (-1,2), L_ORANGE),
    ('BACKGROUND',    (0,3), (-1,3), L_YELLOW),
    ('BACKGROUND',    (0,4), (-1,4), L_GREEN),
    ('BACKGROUND',    (0,5), (-1,5), L_BLUE),
    ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
    ('FONTNAME',      (0,1), (0,-1), 'Helvetica-Bold'),
    ('FONTSIZE',      (0,0), (-1,-1), 7.5),
    ('ALIGN',         (1,0), (3,-1), 'CENTER'),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
    ('TOPPADDING',    (0,0), (-1,-1), 4),
    ('BOTTOMPADDING', (0,0), (-1,-1), 4),
    ('LEFTPADDING',   (0,0), (-1,-1), 4),
    ('RIGHTPADDING',  (0,0), (-1,-1), 4),
]))

# ── Side-by-side comparison table ────────────────────────────────────────────
compare_data = [
    [Paragraph('<b>Feature</b>', hdr_style),
     Paragraph('<b>ESI</b>', hdr_style),
     Paragraph('<b>CTAS</b>', hdr_style)],
    ['Origin / Country', 'USA (AHRQ)', 'Canada (CAEP)'],
    ['Decision Basis', 'Acuity + Expected Resources', 'Chief Complaint + Modifiers + Vitals'],
    ['Time to Complete', '1–2 minutes', '5–10 minutes'],
    ['Mandatory Reassessment', '✗  (only when needed)', '✓  At fixed intervals per level'],
    ['Paediatric Version', 'ESI Paeds (same algorithm)', 'PaedsCTAS (age-adjusted criteria)'],
    ['Reliability (κ)', '0.70–0.90', '0.70–0.95 (highest of all systems)'],
    ['Unique Strength', 'Resource prediction; fast', 'Built-in safety net (reassessment)'],
    ['Main Weakness', 'Resources subjective; variable across countries', 'Complex; requires training; time-intensive'],
    ['Best Setting', 'High-volume US EDs; resource allocation focus', 'Any ED; especially when structured monitoring needed'],
    ['Pain Score Used?', '✓  (for Level 2 consideration)', '✓  (first-order modifier)'],
    ['Vital Sign Threshold', 'Triggers Level 2 upgrade from Level 3', 'Incorporated as modifiers for level adjustment'],
    ['Non-disabling mild symptoms', 'Level 4 or 5', 'Level 4 or 5'],
]
compare_tbl = Table(compare_data, colWidths=[48*mm, 67*mm, 67*mm])
compare_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (-1,0), NAVY),
    ('BACKGROUND',    (0,1), (-1,1), LIGHT_BG),
    ('BACKGROUND',    (0,2), (-1,2), WHITE),
    ('BACKGROUND',    (0,3), (-1,3), LIGHT_BG),
    ('BACKGROUND',    (0,4), (-1,4), WHITE),
    ('BACKGROUND',    (0,5), (-1,5), LIGHT_BG),
    ('BACKGROUND',    (0,6), (-1,6), WHITE),
    ('BACKGROUND',    (0,7), (-1,7), LIGHT_BG),
    ('BACKGROUND',    (0,8), (-1,8), WHITE),
    ('BACKGROUND',    (0,9), (-1,9), LIGHT_BG),
    ('BACKGROUND',    (0,10),(-1,10),WHITE),
    ('BACKGROUND',    (0,11),(-1,11),LIGHT_BG),
    ('BACKGROUND',    (0,12),(-1,12),WHITE),
    ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
    ('FONTNAME',      (0,1), (0,-1), 'Helvetica-Bold'),
    ('FONTSIZE',      (0,0), (-1,-1), 8),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
    ('TOPPADDING',    (0,0), (-1,-1), 4),
    ('BOTTOMPADDING', (0,0), (-1,-1), 4),
    ('LEFTPADDING',   (0,0), (-1,-1), 5),
    ('RIGHTPADDING',  (0,0), (-1,-1), 5),
]))

# ── CTAS Modifiers box ────────────────────────────────────────────────────────
ctas_mod_data = [
    [Paragraph('<b>CTAS Modifiers (Adjust Level Up/Down)</b>', hdr_style)],
    [Paragraph(
        '<b>First-Order (Chief-Complaint Based):</b> Mechanism of injury, acuity of onset, '
        'severity of pain/discomfort (NRS ≥8 → consider upgrading by 1 level)<br/><br/>'
        '<b>Second-Order (Adding Context):</b> Age extremes (&lt;2 yr or &gt;70 yr), '
        'immunocompromised state, mechanism, co-morbidities, patient distress<br/><br/>'
        '<b>Key Rule:</b> Reassessment at mandated intervals is REQUIRED. '
        'If patient deteriorates → upgrade immediately. Document reassessment time.',
        small_style)],
]
ctas_mod_tbl = Table(ctas_mod_data, colWidths=[182*mm])
ctas_mod_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (-1,0), TEAL),
    ('BACKGROUND',    (0,1), (-1,1), HexColor('#E8F4FD')),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('TOPPADDING',    (0,0), (-1,-1), 5),
    ('BOTTOMPADDING', (0,0), (-1,-1), 5),
    ('LEFTPADDING',   (0,0), (-1,-1), 7),
    ('RIGHTPADDING',  (0,0), (-1,-1), 7),
]))

# ── Clinical tips box ─────────────────────────────────────────────────────────
tips_data = [
    [Paragraph('<b>Clinical Decision Tips  — ESI</b>', hdr_style),
     Paragraph('<b>Clinical Decision Tips  — CTAS</b>', hdr_style)],
    [Paragraph(
        '• <b>Disabling deficit</b> at any NIHSS → Level 2 (do not rely solely on NIHSS)<br/>'
        '• Severe pain (NRS ≥8) alone → consider Level 2<br/>'
        '• Normal vitals do NOT rule out Level 2 (high-risk history trumps)<br/>'
        '• "Resources" = distinct services ordered (one CBC = 1, CBC+BMP = still 1 lab draw)<br/>'
        '• CT scan = 1 resource; CT + labs = 2 resources = Level 3 minimum<br/>'
        '• Confused/altered → automatically Level 2<br/>'
        '• Child with fever: apply paediatric danger vital thresholds',
        small_style),
     Paragraph(
        '• Use <b>first positive discriminator</b> — do not skip down flowchart<br/>'
        '• Age &lt;2 or &gt;70 → consider upgrading one level<br/>'
        '• Missed reassessment = patient safety risk — document every interval<br/>'
        '• Pain ≥8/10 → upgrade by 1 level as first-order modifier<br/>'
        '• Immunocompromised patients (HIV, chemo, transplant) → upgrade<br/>'
        '• If in doubt between two levels → always assign the <b>higher acuity</b> level<br/>'
        '• Sepsis criteria present → Level 2 at minimum',
        small_style)],
]
tips_tbl = Table(tips_data, colWidths=[91*mm, 91*mm])
tips_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (0,0), ORANGE),
    ('BACKGROUND',    (1,0), (1,0), TEAL),
    ('BACKGROUND',    (0,1), (0,1), HexColor('#FFF3E0')),
    ('BACKGROUND',    (1,1), (1,1), HexColor('#E0F2FF')),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('VALIGN',        (0,0), (-1,-1), 'TOP'),
    ('TOPPADDING',    (0,0), (-1,-1), 5),
    ('BOTTOMPADDING', (0,0), (-1,-1), 5),
    ('LEFTPADDING',   (0,0), (-1,-1), 6),
    ('RIGHTPADDING',  (0,0), (-1,-1), 6),
]))

# ── Level-to-Level concordance table ─────────────────────────────────────────
concordance_data = [
    [Paragraph('<b>ESI Level</b>', hdr_style),
     Paragraph('<b>Approximate CTAS Equivalent</b>', hdr_style),
     Paragraph('<b>Notes on Differences</b>', hdr_style)],
    ['Level 1 🔴', 'Level 1 🔴', 'Identical — immediate life threat'],
    ['Level 2 🟠', 'Level 2 🟠', 'ESI 2 is slightly broader (includes any high-risk without immediate need)'],
    ['Level 3 🟡', 'Level 2–3 🟠🟡', 'CTAS uses modifiers; ESI 3 with danger vitals → CTAS 2'],
    ['Level 4 🟢', 'Level 4 🟢', 'Very similar — one resource / less urgent'],
    ['Level 5 🔵', 'Level 5 🔵', 'Identical — no resources / non-urgent'],
]
concordance_tbl = Table(concordance_data, colWidths=[35*mm, 55*mm, 92*mm])
concordance_tbl.setStyle(TableStyle([
    ('BACKGROUND',    (0,0), (-1,0), NAVY),
    ('BACKGROUND',    (0,1), (-1,1), L_RED),
    ('BACKGROUND',    (0,2), (-1,2), L_ORANGE),
    ('BACKGROUND',    (0,3), (-1,3), L_YELLOW),
    ('BACKGROUND',    (0,4), (-1,4), L_GREEN),
    ('BACKGROUND',    (0,5), (-1,5), L_BLUE),
    ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
    ('FONTNAME',      (0,1), (0,-1), 'Helvetica-Bold'),
    ('FONTSIZE',      (0,0), (-1,-1), 8),
    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#AABBCC')),
    ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
    ('TOPPADDING',    (0,0), (-1,-1), 4),
    ('BOTTOMPADDING', (0,0), (-1,-1), 4),
    ('LEFTPADDING',   (0,0), (-1,-1), 5),
    ('RIGHTPADDING',  (0,0), (-1,-1), 5),
]))

# ── Footer ────────────────────────────────────────────────────────────────────
footer_data = [[
    Paragraph(
        'ESI: Emergency Severity Index (AHRQ, USA)  |  CTAS: Canadian Triage and Acuity Scale (CAEP)  |  '
        'Pocket guide for clinical reference only — always apply clinical judgement  |  '
        'Compiled June 2026',
        note_style)
]]
footer_tbl = Table(footer_data, colWidths=[182*mm])
footer_tbl.setStyle(TableStyle([
    ('BACKGROUND', (0,0), (-1,-1), LIGHT_BG),
    ('TOPPADDING',    (0,0), (-1,-1), 4),
    ('BOTTOMPADDING', (0,0), (-1,-1), 4),
    ('LEFTPADDING',   (0,0), (-1,-1), 6),
    ('RIGHTPADDING',  (0,0), (-1,-1), 6),
    ('BOX', (0,0), (-1,-1), 0.5, HexColor('#AABBCC')),
]))

# ── Assemble story ────────────────────────────────────────────────────────────
story = [
    title_tbl,
    Spacer(1, 4*mm),

    # Page 1: ESI
    KeepTogether([
        banner('1.  ESI — Emergency Severity Index (USA)', ORANGE),
        Spacer(1, 2*mm),
        banner('1a  ESI Decision Algorithm', TEAL),
        Spacer(1, 1*mm),
        esi_algo_tbl,
        Spacer(1, 2*mm),
    ]),

    KeepTogether([
        banner('1b  ESI — Full Level Details', TEAL),
        Spacer(1, 1*mm),
        esi_levels_tbl,
        Spacer(1, 2*mm),
    ]),

    KeepTogether([
        banner('1c  ESI — Vital Sign Danger Thresholds (trigger Level 2 upgrade)', TEAL),
        Spacer(1, 1*mm),
        vitals_tbl,
        Spacer(1, 3*mm),
    ]),

    # Page 2: CTAS
    KeepTogether([
        banner('2.  CTAS — Canadian Triage and Acuity Scale', ORANGE),
        Spacer(1, 2*mm),
        banner('2a  CTAS Level Reference', TEAL),
        Spacer(1, 1*mm),
        ctas_tbl,
        Spacer(1, 2*mm),
    ]),

    KeepTogether([
        banner('2b  CTAS — Modifiers & Reassessment Rules', TEAL),
        Spacer(1, 1*mm),
        ctas_mod_tbl,
        Spacer(1, 3*mm),
    ]),

    # Comparison section
    KeepTogether([
        banner('3.  ESI vs CTAS — Head-to-Head Comparison', NAVY),
        Spacer(1, 1*mm),
        compare_tbl,
        Spacer(1, 3*mm),
    ]),

    KeepTogether([
        banner('4.  Level Concordance  (ESI ↔ CTAS)', NAVY),
        Spacer(1, 1*mm),
        concordance_tbl,
        Spacer(1, 3*mm),
    ]),

    KeepTogether([
        banner('5.  Clinical Tips at the Triage Desk', NAVY),
        Spacer(1, 1*mm),
        tips_tbl,
        Spacer(1, 3*mm),
    ]),

    footer_tbl,
]

doc.build(story)
print(f"PDF created: {OUTPUT}")

Running Command

python3 /home/daytona/workspace/triage-guide/generate_pocket_guide.py

Running Command

ls -lh /home/daytona/workspace/triage-guide/

Your pocket guide is ready:

ESI vs CTAS Pocket Guide
PDF Document · PDF

What's inside the guide:

Section	Content
1. ESI Decision Algorithm	3-step flowchart (life threat → high risk → resources) with colour coding
2. ESI Full Level Details	All 5 levels with criteria, wait times, and clinical examples
3. ESI Vital Sign Thresholds	Age-stratified danger vitals that trigger Level 2 upgrade
4. CTAS Level Reference	All 5 levels with time-to-physician, mandatory reassessment intervals, examples
5. CTAS Modifiers	First-order and second-order modifier rules + reassessment documentation note
6. Head-to-Head Comparison	12-row feature comparison (origin, basis, reliability, strengths, weaknesses)
7. Level Concordance	ESI ↔ CTAS equivalent mapping with notes on key differences
8. Clinical Tips at the Desk	7 tips each for ESI and CTAS, side by side

Formatted as a colour-coded A4 document with triage-standard red/orange/yellow/green/blue level colours throughout - suitable for printing and laminating for the triage desk.

This is a shared conversation. Sign in to Orris to start your own chat.